Agonistas do receptor de GLP-1 e inibidores da serino-protease dipeptidil-peptidase-4 no tratamento de diabetes tipo 2 - Uma revisão/ GLP-1 receptor agonists and dipeptidyl-peptidase-4 serine protease inhibitors in the treatment of type 2 diabetes - A review

Glauciemar Del-Vechio Vieira, Julianna Oliveira de Lucas Xavier, Jhamine Caroline de Oliveira Freitas, Orlando Vieira de Sousa

Abstract


Diabetes mellitus tipo 2 (DM-2) é uma doença crônica que afeta o metabolismo da glicose devido à resistência à insulina ou ineficiência da sua produção pelas células β-pancreáticas, resultando em hiperglicemia. Entre as opções terapêuticas, os agonistas dos receptores de GLP-1 (glucagon-like peptide-1) e inibidores da enzima serino-protease dipeptidil-peptidase-4 (iDPP-4) têm sido recomendados devido a sua eficácia e menos efeitos adversos, podendo ser prescritos em monoterapia ou em associação com outros antidiabéticos orais ou insulina. A terapia é baseada nos efeitos glicorregulatórios das incretinas, hormônios intestinais produzidos após a ingestão de glicose, e que, entre outros efeitos, são responsáveis pela regulação dos níveis de glicose ao estimularem a secreção de insulina de uma forma dependente desse açúcar. No entanto, embora a farmacologia sobre essa classe de hipoglicemiantes seja bem descrita na literatura, ainda existem dificuldades referentes à compreensão dos mecanismos de ação, efeitos farmacológicos, usos clínicos, efeitos adversos e interações medicamentosas. Neste sentido, uma abordagem direcionada ao entendimento sobre agonistas do receptor de GLP-1 e inibidores da serino-protease dipeptidil-peptidase-4 foi descrita no presente trabalho para fortalecer o conhecimento no seguimento farmacoterapêutico de pacientes com diabetes mellitus tipo 2.


Keywords


Diabetes mellitus, Hipoglicemiante, Agonistas do receptor GLP-1, Inibidores da serino-protease dipeptidil-peptidase-4.

References


AERTGEERTS, K. et al. Crystal structure of human dipeptidyl peptidase IV in complex with a decapeptide reveals details on substrate specificity and tetrahedral intermediate formation. Protein Science, v. 13, n. 2, p. 412–421, 2004.

AHRÉN, B. GLP-1 receptor agonists in the treatment of type 2 diabetes. Diabetes Manage, v. 3, n. 5, p. 401-413, 2013.

ALVES DA CONCEIÇÃO, R.; NOGUEIRA DA SILVA, P.; BARBOSA, M. L. C. Fármacos para o tratamento do diabetes tipo II: uma visita ao passado e um olhar para o futuro. Revista Virtual Química, v. 9, n. 2, p. 514-534, 2017.

ASMA, M.; HOLST, J. J. Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: new advances. Current Opinions in Endocrinology & Diabetes and Obesity, v. 17, n. 1, p. 57-62, 2010.

BERGMAN, A. J. et al. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care, v. 30, n. 7, p. 1862-1864, 2007.

BOND, A. Exenatide (Byetta) as a novel treatment option for type 2 diabetes mellitus. Proceedings (Baylor University. Medical Center), v. 19, n. 3, p. 281-284, 2006.

BOSI, E. et al. Incretin-based therapies in type 2 diabetes: A review of clinical results. Diabetes Research and Clinical Practice, v. 82, p. 102-107, 2008.

BRITO, C. F. et al. Mecanismo de ação das incretinas e o potencial terapêutico de moléculas relacionadas no tratamento do diabetes mellitus tipo 2. Nova: Revista Científica, v. 2, n. 2, p. 1-20, 2013.

CHACRA, A. R. et al. Saxagliptin added to a submaximal dose of sulfonylurea improves glycaemic control compared with uptitration of sulfonylurea in patients with type 2 diabetes: a randomized controlled trial. International Journal of Clinical Practice, v. 63, n. 9, p. 1395-1406, 2009.

CHIA, C. W.; EGAN, J. M. Incretin-based therapies in type 2 diabetes mellitus. Journal of Clinical Endocrinology & Metabolism, v. 93, n. 10, p. 3703-3716, 2008.

DALLA MAN, C. et al. Dipeptidyl peptidase-4 inhibition by vildagliptin and the effect on insulin secretion and action in response to meal ingestion in type 2 diabetes. Diabetes Care, v. 32, n. 1, p. 14-18, 2009.

DAVIDSON, J. A.; PARENTE, E. B.; GROSS, J. L. Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes. Arquivos Brasileiros de Endocrinologia & Metabologia, v. 52, n. 6, p. 1039-1049, 2008.

DEJAGER, S. et al. Vildagliptin in drug-naive patients with type 2 diabetes: a 24-week, doubleblind, randomized, placebo-controlled, multiple-dose study. Hormone and Metabolic Research, v. 39, n. 3, p. 218-23, 2007.

DEL PRATO, S. et al. Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes, Obesity and Metabolism, v. 13, n. 3, p. 258-267, 2011.

DHILLON, S.; WEBER, J. Saxagliptin. Drugs, v. 69, n. 15, p. 2103-2114, 2009.

DICEMBRINI, I.; PALA, L.; ROTELLA, C. M. From theory to clinical practice in the use of GLP-1 receptor agonists and DPP-4 inhibitors therapy. Journal of Diabetes Research, v. 2011, art. ID 898913, p. 1-8, 2011.

DRUCKER, D. J. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes. Diabetes Care, v. 30, n. 6, p. 1335-1343, 2007.

FERREIRA, V. A.; CAMPOS, S. M. B. Avanços farmacológicos no tratamento do diabetes tipo 2. Brazilian Journal of Surgery and Clinical Research – BJSCR, v. 8, n. 3, p. 72-78, 2014.

FONSECA, V. A. et al. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo controlled trial in patients with Type 2 diabetes (GetGoal-Mono). Diabetes Care, v. 35, n. 6, p. 1225-1231, 2012.

FONSECA, V. et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia, v. 50, n. 6, p. 1148-1155, 2007.

FORST, T. et al. Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes. Diabetic Medicine, v. 27, n. 12, p. 1409-1419, 2010.

FORST, T. et al. The oral DPP4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism, v. 13, n. 6, p. 542-550, 2011.

FRANK, T. Population pharmacokinetics of lixisenatide, a once-daily human glucagon-like peptide-1 receptor agonist, in healthy subjects and in patients with type 2 diabetes. Journal of Pharmaceutics & Drug Delivery Research, v. 2, n. 1, p. 1-10, 2013.

GALLWITZ, B. New therapeutic strategies for the treatment of type 2 diabetes mellitus based on incretins. Review of Diabetic Studies, v. 2, n. 2, p. 61-69, 2005.

GALLWITZ, B. Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, v. 6, p. 1-9, 2013.

GALLWITZ, B. Glucagon-like peptide-1 and gastric inhibitory polypeptide: new advances. Current Opinions in Endocrinology & Diabetes and Obesity, v. 23, n. 1, p. 23-27, 2016.

GOMIS, R. et al. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes, Obesity and Metabolism, v. 13, p. 653-661, 2011.

GRAEFE-MODY, U. et al. Pharmacokinetics of linagliptin in subjects with hepatic impairment. British Pharmacological Society, v. 74, n. 1 p. 75-85, 2012.

GREEN, B. D.; FLATT, P. R. Incretin hormone mimetics and analogues in diabetes therapeutics. Best Practice & Research Clinical Endocrinology & Metabolism, v. 21, n. 4, p. 497-516, 2007.

GRIGOROPOULOU, P. et al. Incretin-based therapies for type 2 diabetes mellitus: effects on insulin resistance. Current Diabetes Reviews, v. 9, n. 5, p. 412-417, 2013.

GUPTA, V. Glucagon-like peptide-1 analogues: an overview. Indian Journal of Endocrinology and Metabolism, v. 17, n. 3, p. 413-421, 2013.

HERMAN, G. A. et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. Journal of Clinical Endocrinology & Metabolism, v. 91, n. 11, p. 4612–4619, 2006.

HINNEN, D. et al. Incretin mimetics and DPP-IV inhibitors: new paradigms for the treatment of type 2 diabetes. Journal of the American Board of Family Medicine, v. 19, n. 6, p. 612-620, 2006.

HOLST, J. J. From the incretin concept and the discovery of GLP-1 to today's diabetes therapy. Frontiers in Endocrinology, v. 10, p. 1-10, 2019a.

HOLST, J. J. The incretin system in healthy humans: The role of GIP and GLP-1. Metabolism Clinical and Experimental, v. 96, p. 46-55, 2019b.

HOLLANDER, P. et al. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. Journal of Clinical Endocrinology and Metabolism, v. 94, n. 12, p. 4810-4819, 2009.

INZUCCHI, S. E. et al. New drugs for the treatment of diabetes - Part II: incretin-based therapy and beyond. Circulation, v. 117, n. 4, p. 574-584, 2008.

JADZINSKY, M. et al. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes, Obesity and Metabolism, v. 11, n. 6, p. 611-622, 2009.

JIMENEZ-SOLEM, E. et al. Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of Type 2 diabetes. Current Opinion in Molecular Therapeutics, v. 12, n. 6, p. 790-797, 2010.

KALRA, S. et al. Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and future. Indian Journal Endocrinology and Metabolism, v. 20, n. 2, p. 254-267, 2016.

KAPITZA, C. et al. Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin. Diabetes, Obesity & Metabolism, v. 15, n. 7, p. 642-649, 2013.

KHAWANDANAH, J. Double or hybrid diabetes: A systematic review on disease prevalence, characteristics and risk factors. Nutrition & Diabetes, v. 9, n. 33, p. 1-9, 2019.

LI, F-f. et al. Effects of saxagliptin add-on therapy to insulin on blood glycemic fluctuations in patients with type 2 diabetes: A randomized, control, open-labeled trial. Medicine (Baltimore), v. 95, n. 43, p. 1-5, 2016.

LORENZ, M. et al. Effects of lixisenatide once daily on gastric emptying in type 2 diabetes - relationship to postprandial glycemia. Regulatory Peptides, v. 185, p. 1-8, 2013.

LOVSHIN, J. A.; DRUCKER, D. J. Incretin-based therapies for type 2 diabetes mellitus. Nature Reviews Endocrinology, v. 5, n. 5, p. 262-269, 2009.

MARÍN-PEÑALVER, J. J. et al. Update on the treatment of type 2 diabetes mellitus. World Journal of Diabetes, v. 7, n. 17, p. 354-395, 2016.

McGILL, J. B. Impact of incretin therapy on islet dysfunction: an underlying defect in the pathophysiology of type 2 diabetes. Postgraduate Medicine, v. 121, n.1, p. 46-58, 2009.

MEIER, J. J.; NAUCK, M. A. Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired β-cell function? Diabetes, v. 59, p. 1117-1124, 2010.

MOUHAYYAR, C. E. et al. SGLT2 inhibitors, GLP-1 agonists, and DPP-4 inhibitors in diabetes and microvascular complications: A Review. International Journal of Endocrinology, v 2020, p. 1-11, 2020.

NAUCK, M. A.; BALLER, B.; MEIER, J. J. Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes. Diabetes, v. 53, Suppl. 3, p. S190-S196, 2004.

NAUCK, M. A. et al. The once-weekly human GLP-1 analogue semaglutide provides significant reductions in HbA1c and body weight in patients with Type 2 diabetes. Diabetologia, v. 55, Suppl. 1, p. S7, 2012.

NOGUEIRA, M. et al. Pharmaceutical care-based interventions in type 2 diabetes mellitus: a systematic review and meta-analysis of randomized clinical trials. Einstein (São Paulo), v. 18, p. 1-14, 2020.

OLOKOBA, A. B.; OBATERU, O. A.; OLOKOBA, L. B. Type 2 diabetes mellitus: A review of current trends. Oman Medical Journal, v. 27, n. 4, p. 269-273, 2012.

ORIÁ, R. B.; BRITO, G. A. C. Sistema Digestório - Integração Básico-Clínica. 1ª ed., São Paulo, Editora Edgard Blucher Ltda., 2016. 837p.

OWENS, D. R. et al. Efficacy and safety of linagliptin in persons with Type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study. Diabetic Medicine, v. 28, n. 11, p. 1352-1361, 2011.

PETERSEN, A. B.; KNOP, F. K.; CHRISTENSEN, M. Lixisenatide for the treatment of type 2 diabetes. Drugs of Today, v. 49, n. 9, p. 537-553, 2013.

PINKNEY, J.; FOX, T.; RANGANATH, L. Selecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatide. Therapeutics and Clinical Risk Management, v. 6, p. 401-411, 2010.

PRATLEY, R. E.; GILBERT, M. Targeting incretins in type 2 diabetes: role of GLP-1 receptor agonists and DPP-4 inhibitors. The Review of Diabetic Studies, v. 5, n. 2, p. 73-94, 2008.

PRODANOV, C. C.; FREITAS, E. C. Metodologia do trabalho científico: métodos e técnicas da pesquisa e do trabalho acadêmico. 2ª ed., Novo Hamburgo, RS, Editora FEEVALE, 2013. 277p.

ROSENSTOCK, J. et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo controlled, parallel-group study. Clinical Therapeutics, v. 28, n. 10, p. 1556-1568, 2006.

ROSENSTOCK, J. et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care, v. 30, p. 217-223, 2007.

ROSENSTOCK, J. et al. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care, v. 31, n. 1, p. 30-35, 2008.

ROSENSTOCK, J. et al. Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes. Current Medical Research and Opinion, v. 25, n. 10, p. 2401-2411, 2009.

ROSENSTOCK, J. et al. Efficacy and safety of lixisenatide once daily versus exenatide twice daily in Type 2 diabetes inadequately controlled on metformin: a 24-week randomized, open-label, active-controlled study (GetGoal-X). Diabetes Care, v. 36, n. 10, p. 2945-2951, 2013.

SAMI, W. et al. Effect of diet on type 2 diabetes mellitus: A review. International Journal of Health Sciences, v. 11, n. 2, p. 65-71, 2017.

SCHERNTHANER, G. et al. Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism, v. 14, p. 470-478, 2012.

SCHNABEL, C. A; WINTLE, M.; KOLTERMAN, O. Metabolic effects of the incretin mimetic exenatida in the treatment of type 2 diabetes. Vascular Health and Risk Management, v. 2, n. 1, p. 69-77, 2006.

SHARMA, M. D. Role of saxagliptin as monotherapy or adjunct therapy in the treatment of type 2 diabetes. Therapeutics and Clinical Risk Management, v. 6, p. 233-237, 2010.

SORTINO, M. A.; SINAGRA, T.; CANONICO, P. L. Linagliptin: A thorough characterization beyond its clinical efficacy. Frontiers in Endocrinology, v. 4, p. 1-9, 2013.

ST ONGE, E. L.; MILLER, S. A. Albiglutide: a new GLP-1 analog for the treatment of Type 2 diabetes. Expert Opinion on Biological Therapy, v. 10, n. 5, p. 801-806, 2010.

TASYUREK, H. M. et al. Incretins: Their physiology and application in the treatment of diabetes mellitus. Diabetes/Metabolism Research and Reviews, v. 30, p. 354-371, 2014.

THORNBERRY, N. A.; GALLWITZ, B. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Best Practice & Research Clinical Endocrinology & Metabolism, v. 23, n. 4, p. 479-486, 2009.

VELLA, A. Mechanism of action of DPP-4 inhibitors — new insights. Clinical Endocrinology & Metabolism, v. 97, n. 8, p. 2626-2628, 2012.

VELLA, A. et al. Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes, v. 56, n. 5, p. 1475-1480, 2007.

ZIERATH, J. R. Major advances and discoveries in diabetes - 2019 in review. Current Diabetes Reports, v. 19, n. 11, p. 118-126, 2019.




DOI: https://doi.org/10.34119/bjhrv3n4-036

Refbacks

  • There are currently no refbacks.